The Chronic Care Policy Alliance (CCPA) submitted comprehensive comments to the Centers for Medicare & Medicaid Services (CMS) regarding all 15 medications included in the second round of the Medicare Drug Price Negotiation Program (MDPNP) under the Inflation Reduction Act (IRA). CCPA’s focus is on supporting lower medications cost while ensuring these efforts don’t unintentionally limit access to essential medications for patients with chronic conditions.
CCPA raised concerns that price negotiations could lead to increased utilization management, creating barriers such as prior authorization or step therapy that delay care. These delays could worsen health outcomes, particularly for patients with chronic diseases. CCPA cautioned CMS about the negative effects these negotiations could have on research and innovations, which are critical for developing future treatments. CCPA is also concerned that the variety of medications remain available to patients, as the same medication does not work for all people. In addition, we highlighted the risk of limited access for vulnerable populations, such as those in rural areas, due to reduced reimbursement rates and pharmacy consolidations.
As a patient-first organization, CCPA has consistently advocated for a balanced approach to healthcare reforms. We urge policymakers to prioritize reforms that directly benefit patients, such as Pharmacy Benefit Manager (PBM) reform, and to engage with patient voices throughout the policy-making process. As the negotiation process moves forward, CCPA will continue to fight on behalf of patients, ensuring their needs are front and center in every discussion.